Hypothyroidism – Medxy AI

Phase 2 Study of XP-8121: Once-Weekly Subcutaneous Levothyroxine for Adult Hypothyroidism

By MedXY 06/05/2026

A Phase 2 trial found that once-weekly subcutaneous levothyroxine (XP-8121) was generally well tolerated and suggested a dose conversion of about four times the daily oral dose for adults with hypothyroidism.

Diabetes & Endocrinology news OB/GYN & Women’s Health

Long-Term Risk of Hypothyroidism After Thyroid Abnormalities Identified in Pregnancy

By MedXY 06/04/2026

Thyroid abnormalities found during pregnancy, especially when subclinical hypothyroidism and TPO antibodies coexist, can signal a much higher long-term risk of overt hypothyroidism, supporting ongoing thyroid follow-up after delivery.

Diabetes & Endocrinology Internal Medicine news

Breaking the Fasting Mandate: Is It Time to Re-evaluate Levothyroxine Administration?

By MedXY 03/18/2026

A randomized clinical trial demonstrates that a 15% dose increase allows levothyroxine to be taken with breakfast without compromising TSH stability, significantly improving patient preference and well-being.

Diabetes & Endocrinology news

Levothyroxine Monotherapy in Midlife Women: Long-Term SWAN Data Reassures on Cardiovascular Safety

By MedXY 03/12/2026

A longitudinal analysis from the SWAN study indicates that women treated with levothyroxine for hypothyroidism do not face a higher risk of cardiovascular events compared to those without thyroid disease, providing clinical reassurance for long-term management during the menopause transition.